Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Pan American Silver Corp. Common Stock (PAAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Pan American Silver Corp. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Pan American Silver Corp. Common Stock trades at $43.24 (market cap $17.55B). The key difference: Pan American Silver Corp. Common Stock is far larger — about 6.2× Dyne Therapeutics Inc. Common Stock's market cap, and Pan American Silver Corp. Common Stock pays a 1.74% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Pan American Silver Corp. Common Stock for 2 Days on average.
| DYN | PAAS | |
|---|---|---|
Market Cap | $2.81B | $17.55B |
Volume | 2,195,902 | 6,423,301 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $68.70 |
52-Week Low | $14.60 | $33.20 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $2.13B | $16.69B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Pan American Silver Corp. Common Stock
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →
